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Introduction
Female genital tract sarcomas are rare malignant gyne-
cologic tumors. They may arise from the mesenchy-
mal tissues of the whole female genital tract, namely,
from the vulva to the Fallopian tubes, although most
mesenchymal tumors occur in the uterine corpus. De-
spite the relatively low incidence of these tumors, they
are usually highly malignant with the exception of a
few specific types such as low-grade endometrial stro-
mal sarcoma and adenosarcoma. For example, carcino-
sarcomas and other uterine sarcomas account for
fewer than 4% of all cancers of the uterine corpus. How-
ever, in a national database, they comprised 26% of
deaths due to uterine corpus malignancies.1 An aggres-
sive growth pattern with early lymphatic or hematoge-
nous dissemination is a typical clinical course. The other
reason for the poor outcome of these tumors may be
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their poor response to chemotherapy. The overall sur-
vival rate for carcinosarcoma, high-grade leiomyosar-
coma, and high-grade endometrial stromal sarcoma is
poor, and death often occurs within 1 or 2 years of
diagnosis.2
Because of the rare occurrence of female genital
tract sarcoma, there have been few reports of patho-
genetic studies of such tumors, especially with regard
to molecular analysis. Frequent TP53 mutation with
resultant overexpression of TP53 protein has been
noted in uterine and ovarian sarcomas.3 Reports of
other apoptosis-related factors such as BCL-2, BAX
and c-MYC, however, are rare, and most of them
focused on uterine sarcoma.4–6 Because deregulation
of the apoptosis pathway is related to tumorigenesis
and chemodrug resistance, studying the expression
status and relationship of these factors in this group of
tumors is of vital importance. It may aid in the under-
standing of the mechanism of pathogenesis and why
these tumors are clinically so aggressive. In addition,
understanding molecular abnormalities in neoplasm
may help in the design of anticancer agents for targeted
therapy that can reverse defective molecules.7–9
The purpose of this study was to examine the pro-
tein expression of the apoptosis-related markers BCL-
2, BAX and c-MYC in female genital tract sarcomas.
The relationships among them and with TP53 muta-
tion were analyzed. In addition, the correlations of these
markers with clinicopathologic findings and their prog-
nostic significance were also examined.
Methods
Tissue specimens and review
Joint Institutional Review Board approval was ob-
tained prior to conducting this investigation. Fifty-four
patients with primary or recurrent sarcoma of the
genital tract were recruited. All of these patients un-
derwent surgical intervention at either Taichung or
Taipei Veterans General Hospital between 1992 and
2006 (43 patients received operation in 2000 or
later). Their medical records were reviewed and the
survival time was followed to either death or December
31, 2006. The stage of disease was assigned based on
the International Federation of Gynecology and Ob-
stetrics (FIGO) staging system for carcinoma of the
vagina, cervix, uterus, fallopian tube or ovary accord-
ing to the origin of the sarcoma. All histopathology
slides were reviewed by pathologists at these 2 hospi-
tals to confirm the diagnosis, and tumor-rich paraffin
blocks were selected for immunohistochemical (IHC)
study.
IHC staining
Paraffin sections of 4μm were dewaxed, rehydrated, and
then heated with citrate buffer (pH 6.0). After being
rinsed in phosphate-buffered saline (pH 7.6) and pre-
incubated in serum blocking solution (10% goat serum),
slides were reacted with the primary antibodies, i.e.
anti-TP53, BCL-2, c-MYC mouse monoclonal anti-
bodies (DAKO, Carpinteria, CA, USA; clones DO-7,
124 and 9E10) and anti-BAX rabbit polyclonal anti-
body (DAKO). The anti-TP53 antibody is a recombi-
nant human wild-type TP53 protein, which labels
wild-type and mutant-type TP53 protein when accu-
mulated in human neoplasias.
The antibodies were used at dilutions of 1:300,
1:150, 1:800, and 1:400 for TP53, BCL-2, c-MYC, and
BAX, respectively. Following incubation with the biotin-
ylated secondary antibody (Histostain-Plus kit; Zymed,
South San Francisco, CA, USA) and peroxidase-labeled
streptavidin (Zymed LAB-SA), slides were rinsed again
and were developed with the enzyme substrate diamino-
benzidine. Tumor tissues known to be positive for the
specific markers were used as positive controls: they
were colon carcinoma for TP53, lymphoma for BCL-
2, cervical carcinoma for c-MYC, and prostate carci-
noma for BAX. Another tumor tissue treated with the
same procedures but which was not incubated with
primary antibody was used as negative control.
Assessment of immunoreactivity
The expressions of BCL-2, BAX and c-MYC were
scored according to the extent and intensity of cytoplas-
mic immunoreactivity using a semiquantitative evalu-
ation.10 When the extent of immunoreactivity in the
cytoplasm of tumor cells was < 15%, it was scored as 
1 point; if 15–50% of tumor cells were positive, 2 points;
and 3 points if > 50% of tumor cells were stained in
the cytoplasm. The intensity of cytoplasmic staining
was subjectively graded as weak (1 point), moderate
(2 points) or intense (3 points). IHC evaluation and
scoring were determined by 2 of the authors (FSL and
YJJ). The product of the extent score multiplied by
the intensity score was the final IHC score of BCL-2,
BAX and c-MYC. The same calculation was used for
TP53, but only nuclear staining was regarded as posi-
tive. Cases that had a final IHC score < 4 were consid-
ered to be negative and those with final IHC score ≥ 4
were considered to be positive.
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 10.0 (SPSS Inc., Chicago, IL, USA). The correla-
tions between the expression of each apoptotic marker
and pathologic type as well as disease progression were
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examined by Yate’s correction of contingency or Fisher’s
exact test. Because the case number was limited, disease
status was grouped into early stage (FIGO stages I/II)
and late stage (FIGO stages III/IV) in the analysis. The
relationships among TP53, BCL-2, BAX and c-MYC
were examined using Spearman’s correlation analysis.
For survival analysis, the operation dates of the patients
were considered as the start time of the research. Data
on survival were censored if the patient was still alive
at the time of the last follow-up. The relation between
the expression of each apoptotic marker and outcome
was examined by log rank analysis. Survival curves and
median follow-up time among survivors were estimated
according to the Kaplan-Meier method, and p values
were derived by the log-rank test. Hazard ratios for the
risk of death were computed using a Cox proportional
hazards model. Factors that showed a relationship with
survival in the univariate analysis (p<0.05) were entered
into a multivariate Cox model. A p value less than 0.05
was considered statistically significant.
Results
Patient characteristics
Among the 54 cases with genital tract sarcoma, 26 were
leiomyosarcoma, 14 were carcinosarcoma, 6 were endo-
metrial stromal sarcoma (ESS), 3 were sarcoma bot-
ryoides, 3 were undifferentiated sarcoma, and 2 were
adenosarcoma. Forty-seven tumors primarily originated
from the uterine corpus. They were: leiomyosarcoma,
26 cases; carcinosarcoma, 11 cases; ESS, 5 cases; un-
differentiated sarcoma, 3 cases; and adenosarcoma, 
2 cases. Two cases of carcinosarcoma and 1 case of ESS
were of ovarian origin. The remaining 4 tumors arose
from the cervix (sarcoma botryoides: 2 cases), fallopian
tube (carcinosarcoma: 1 case), and vagina (sarcoma bot-
ryoides: 1 case). Thirty patients had stage I/II disease
and 23 patients had stage III/IV disease at the time
of surgery. The stage was unknown for 1 patient with
uterine leiomyosarcoma who received initial surgery
at another hospital. Median patient age was 56 years
(range, 3–80 years). The demographic characteristics
of the patients are summarized in Table 1. The median
overall survival for the 54 patients was 44 months (95%
CI, 19–69), and median follow-up time for the censored
patients was 38 months (range, 7–185 months).
IHC results
The results of IHC staining are summarized in Table 2.
Of the 54 cases, 24 (44%) were positive for TP53, 23
(43%) for BCL-2, 25 (46%) for BAX, and 30 (56%) for
c-MYC. Examples of the IHC staining are shown in
Figure 1.
The protein expression patterns of these apoptotic
markers in the subgroups of leiomyosarcoma and 
Table 1. Patients’ demographic characteristics
Median age, yr (range) 56 (3–80)






Tumor histology, n (%)
Leiomyosarcoma 26 (48.1)
Carcinosarcoma 14 (25.9)
Endometrial stromal sarcoma 6 (11.1)
Sarcoma botryoides 3 (5.6)
Undifferentiated sarcoma 3 (5.6)
Adenosarcoma 2 (3.7)




Fallopian tube 1 (1.9)
Vagina 1 (1.9)
Table 2. Protein expression of apoptosis-related markers in female genital tract sarcomas*
IHC staining Total (n = 54) Leiomyosarcoma (n = 26) Carcinosarcoma (n = 14) p
TP53 (+)† 24 (44.4) 13 (50.0) 9 (64.3) 0.594§
TP53 (−)‡ 30 (55.6) 13 (50.0) 5 (35.7)
BCL-2 (+) 23 (42.6) 12 (46.2) 5 (35.7) 0.763§
BCL-2 (−) 31 (57.4) 14 (53.8) 9 (64.3)
BAX (+) 25 (46.3) 11 (42.3) 9 (64.3) 0.320§
BAX (−) 29 (53.7) 15 (57.7) 5 (35.7)
c-MYC (+) 30 (55.6) 17 (65.4) 9 (64.3) 1.000||
c-MYC (−) 24 (44.4) 9 (34.6) 5 (35.7)
*Data presented as n (%); †IHC staining score ≥ 4; ‡IHC staining score < 4; §Yate’s correction of contingency; ||Fisher’s exact test.
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carcinosarcoma are also shown in Table 2. No significant
difference was noted between these 2 major types of
sarcoma.
TP53, BCL-2, BAX, and c-MYC associations
The correlations among TP53, BCL-2, BAX and c-MYC
were analyzed. BCL-2, BAX and c-MYC protein expres-
sions were not associated with TP53 protein accumu-
lation. There was also no correlation between BCL-2
and BAX, or between BCL-2 and c-MYC. However, a
significant positive association was observed between
BAX and c-MYC expression (p < 0.001) (Table 3).
Association of IHC staining and stage
To assess whether change in the apoptotic markers is
associated with disease development, tumors were
divided into early stage (stage I/II) and late stage (stage
III/IV). Statistical analysis revealed no significant differ-
ence between expression status of the individual apop-
totic markers and disease stage (Table 4).
Overall survival analysis
Survival status information was available for each of
the 54 patients, which included 29 deaths. Expression
of TP53, BCL-2, BAX and c-MYC was compared in
positive and negative groups for overall survival. Only
patients with TP53-positive tumors had significantly
A B
C D
Figure 1. Immunohistochemical staining of apoptosis-related markers (400×): (A) TP53 in a carcinosarcoma (score: 9); (B) c-MYC in a
carcinosarcoma (score: 9); (C) BCL-2 in a leiomyosarcoma (score: 9); (D) BAX in a leiomyosarcoma (score: 6).
Table 3. Spearman’s correlation analysis of TP53, BCL-2, BAX and
c-MYC expression
TP53 BCL-2 BAX c-MYC
TP53 1.000
BCL-2 −0.081 1.000
BAX 0.088 −0.226 1.000
c-MYC 0.214 −0.141 0.497* 1.000
*p < 0.001.
Table 4. Correlation between stage and TP53, BCL-2, BAX and c-
MYC expression*
IHC staining Stage I/II Stage III/IV p†
(n = 30) (n = 23)
TP53 (+)‡ 15 (50.0) 9 (39.1) 0.610
TP53 (−)§ 15 (50.0) 14 (60.9)
BCL-2 (+) 13 (43.3) 10 (43.5) 1.000
BCL-2 (−) 17 (56.7) 13 (56.5)
BAX (+) 13 (43.3) 11 (47.8) 0.962
BAX (−) 17 (56.7) 12 (52.2)
c-MYC (+) 16 (53.3) 13 (56.5) 1.000
c-MYC (−) 14 (46.7) 10 (43.5)
*Data presented as n (%); †Yate’s correction of contingency; ‡IHC staining
score ≥ 4; §IHC staining score < 4.
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poorer survival than those with TP53-negative tumors
(p = 0.039) (Figure 2). In addition, patients with
stage I/II had significantly longer survival than those
with stage III/IV (p = 0.0016) (Figure 3). In univari-
ate analysis, age was another factor that correlated
with survival, i.e. patients of older age had poorer
prognosis (p < 0.05 by Wald statistic). When TP53,
stage and age were jointly analyzed using the Cox
proportional hazards model with death as the end-
point, these 3 factors were still independent prognos-
tic factors for overall survival (Table 5).
Discussion
It is widely known that cancer is a disease involving
deregulated proliferation and programmed cell death.
The net result of these 2 processes determines if the
cancer cell number increases or decreases. Kinetic
studies have implied that cell loss, rather than cell pro-
liferation, indeed controls the rate of tumor growth.11,12
For example, the fraction of cell loss in the range of
70% to more than 95% in most solid tumors has been
reported.13 Therefore, changes in the rate of cell
death could have a major impact on tumor growth or
regression.
The pathway of programmed cell death (also known
as apoptosis) has been extensively studied and is delin-
eated in review literature.14–16 Briefly, the various sig-
nals that elicit apoptosis converge on the mitochondria,
which in turn release cytochrome c into the cytosol,
where it triggers activation of caspases, a series of
enzymes considered to comprise the engine of apop-
totic cell death, by formation of the adapter/caspase
complexes, which then activate the downstream caspase
cascade and finally cause cell death through selective
destruction of subcellular structures, organelles, and
the genome.
BCL-2 family proteins serve as critical regulators
in the pathway of apoptosis. The apoptosis-suppressing
BCL-2 gene promotes cell survival by blocking 
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Figure 2. Kaplan-Meier survival curves of genital tract sarcoma






































Figure 3. Kaplan-Meier survival curves of genital tract sarcoma
stratified for tumor stage.
Table 5. Analysis of prognostic value of clinical factors and apoptotic markers
Univariate Cox regression Multivariate Cox regression
p* HR (95% CI) p HR (95% CI)
Stage 0.003 3.27 (1.49, 7.14) 0.003 3.63 (1.56, 8.44)
Age 0.007 1.04 (1.01, 1.07) 0.019 1.04 (1.01, 1.07)
TP53 0.046 2.12 (1.01, 4.44) 0.004 3.37 (1.48, 7.69)
BCL-2 0.686 1.17 (0.56, 2.45) NS
BAX 0.147 1.73 (0.82, 3.65) NS
c-MYC 0.218 1.62 (0.75, 3.51) NS
*Wald statistic. HR = hazard ratio; CI = confidence interval; NS = not significant.
with the mitochondria-mediated cell death pathway
at 2 points, i.e. preventing cytochrome c release from
mitochondria and interfering with the adapter protein
Apaf-1.17 To date, at least 15 BCL-2 family member
proteins have been identified, including proteins that
promote apoptosis such as BAX and BAD, and those
that prevent apoptosis such as BCL-2 and BCL-XL.18
These member proteins can act independently and
they also have the ability to compete or inhibit one
another in the apoptotic process. Overexpression of
BCL-2 protein also prevents cell death induced by
nearly all cytotoxic anticancer drugs and radiation,
thus contributing to treatment failures in patients
with some types of cancer.19,20
Tumor suppressor genes and oncogenes are also
associated with the regulation and execution of apop-
tosis, most notably TP53 and c-MYC.14–16 TP53 can
promote apoptosis through the upregulation of BAX
and the downregulation of BCL-2.21 When TP53 is
mutated, the functional inactivation of its protein
product may result in the removal of a key compo-
nent of the DNA damage sensor that can induce the
apoptotic effector cascade. In addition to its well-
documented growth-promoting property, c-MYC has
been found to be a powerful inducer of apoptosis
through TP53-dependent and independent path-
ways, and both pathways may facilitate cytochrome c
release from mitochondria. On the other hand, BCL-2
allows c-MYC-induced proliferation to proceed with-
out apoptosis and thus to potentiate its oncogenic
action.
Although BCL-2 is involved in neoplastic transfor-
mation and conferred tumor resistance to chemother-
apy, paradoxically, retrospective archival studies of
non-small cell lung, breast, and ovarian carcinomas
suggest that BCL-2 expression is associated with a
survival advantage.22–24 Similarly, in contrast to its apop-
tosis promoter function, high expression of bax in ovar-
ian cancer has a negative impact on treatment response
and survival.25
In this study, we examined protein expression of the
apoptosis-related markers in female genital tract sar-
comas. TP53, BCL-2, BAX and c-MYC were all fre-
quently expressed in this group of tumors. This finding
is compatible with previous observations in uterine sar-
comas.4–6 All of these protein changes occurred in both
early- and late-stage diseases, with no difference in
frequency. Therefore, changes in the apoptotic path-
way and cell cycle deregulation may be early events in
the development of this group of tumors. As far as the
correlations among these markers are concerned, we
noted a significant positive relationship between BAX
and c-MYC. This finding is compatible with previous
in vitro and in vivo studies that BAX is activated and
required in c-MYC-induced apoptosis.26–30 Albihn et al
observed that etoposide- and doxorubicin-induced
cell death was potentiated via c-MYC/BAX apoptosis.31
The clinical significance of this finding remains to be
investigated, however. In our 54 studied patients, 17
had tumors showing positive c-MYC and BAX. Only
3 patients are still alive with survival time from 18 to
135 months. In addition, their tumors were all in the
early stage (1 cervical sarcoma botryoides, 2 carcino-
sarcomas). In another study, Taylor et al noted that
oncogene-mediated induction of BAX was necessary
but insufficient to enhance TP53-mediated apoptosis
in rhabdomyosarcoma cells and that expression of all
3 proteins, MYC, BAX and TP53, was required for
maximal cell death to occur.32
The prognostic significance of TP53, BCL-2, BAX
and c-MYC was evaluated individually. Among these
4 markers, only expression of TP53 possessed a prog-
nostic significance in both univariate and multivariate
analyses, where patients with TP53-positive tumors
had a poorer overall survival than those with TP53-
negative tumors. This finding suggests that aggressive
management in patients with TP53-positive tumors
may be necessary even in the early stage.
In our study, BCL-2 was also expressed frequently
in uterine leiomyosarcomas and other female genital
tract sarcomas. However, it showed no association with
the other 3 studied markers, nor did it have prognostic
significance in these tumors. In the study of Leiser et al,
BCL-2 positive leiomyosarcomas were associated with
a longer time to recurrence in univariate analysis, but
it was no longer an independent significant prognos-
tic factor when evaluated in multivariate analysis.6 There-
fore, change in BCL-2 is likely as the c-MYC/BAX
apoptotic pathway, although present, is not pivotal in
the development of female genital tract sarcoma.
In conclusion, we observed that the apoptosis-
related proteins TP53, BCL-2, BAX and c-MYC were
overexpressed frequently in female genital tract sarco-
mas. Change in the expression of these proteins may
occur early in the development of this group of tumors,
in which the c-MYC/BAX pathway and BCL-2 may
play roles in tumor apoptosis. However, TP53 muta-
tion may be more pivotal in this process, and clini-
cally, it could be used as a prognostic indicator.
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